Recently, Raymon Pharma announced that the clinical trial of self-developed RA1115-B1 eye drops for the treatment of neovascular (wet) age-related macular degeneration (wAMD) was launched in China. The Phase I clinical trial at Peking Union Medical College Hospital of the Academy of Medical Sciences, chaired by the principal investigators Professor Youxin Chen and Associate Professor Rui Che, has been completed with positive results.
In the research and development of RA1115-B1 eye drops, Shanghai Medicilon Inc. (Medicilon) provided pharmaceutical research services such as raw material drug production, raw material drug process development, and preparation prescription process development to accelerate the R&D process.
Wet age-related macular degeneration is a vision killer for middle-aged and elderly people. Among the irreversible blinding eye diseases in the world according to WHO statistics, wet age-related macular degeneration occupies the second place. In China, the prevalence rate of people over 50 years old has reached more than 15%, and it gradually increases with age.
RA1115-B1 eye drops are innovative in both mechanism of action and mode of administration. As a VEGF inhibitor, RA1115-B1 can block the phosphorylation of VEGFr-2 and inhibit the adhesion, proliferation and migration of endothelial cells induced by VEGF, reduce pathological vascular proliferation, and then reduce the impact of leakage and hemorrhage on the retina and to achieve the effect of improving eyesight. The data of this phase I clinical study showed that RA1115-B1 eye drops showed superior safety, tolerability and pharmacokinetic characteristics in healthy subjects.
This progress also means that Raymon Pharma has taken another solid step in the field of ophthalmology, and fully proves the R&D capabilities of Raymon Pharma drug chemistry design platform and the hard core strength of "source innovation".
Medicilon, which has also been deeply involved in the field of ophthalmic drugs for many years, has also been committed to researching advanced ophthalmic preclinical drug trials and in-depth analysis, and has built a Medicilon preclinical ophthalmology research platform. RA1115-B1 eye drop is an epitome of Medicilon's ophthalmic drug R&D service platform serving new drug R&D with professional capabilities.
In terms of pharmaceutical research, the Medicilon Process Department has a cGMP raw material drug production line that complies with both US and China IND, and can provide innovative process R&D and large-scale production services. The Medicilon Preparation Department can provide prescription research, process research, packaging material research and more. In addition to eye drops, Medicilon can also develop ophthalmic preparations for gels, ointments, creams, and injections. In terms of preclinical research, Medicilon can achieve unique and precise drug administration for animal species such as rabbits, dogs, miniature pigs and non-human primates, including subretinal injection, suprachoroidal injection and vitreous injection to provide clients with stable and high-quality research services.
The demand for ophthalmology continues to release, and the research and development of new drugs has a long way to go. Medicilon is delighted that the phase I clinical trial of Raymon Pharma's new drug RA1115-B1 eye drops has achieved positive results, showing good therapeutic potential. It is hoped that it can go further in the next clinical trials and open up a new path for the treatment of wAMD. At the same time, Medicilon will continue to expand innovative technologies in the field of ophthalmic drugs, and help more ophthalmic drugs to achieve "acceleration" in research and development!
About Raymon Pharma
Raymon Pharma was established in March 2018 which focusing on the research and development of innovative ophthalmic drugs and located in Biobay, the Biomedical Industrial Park in Suzhou Industrial Park. Raymon Pharma has been committed to the development and clinical research of new drugs for ophthalmological blinding diseases, and has already deployed research on various ophthalmic diseases. In the future, Raymon Pharma will continue to adhere to the concept of "science and technology for the benefit of health", benchmark the areas of unmet clinical needs, further expand new pipelines, and promote the research of innovative ophthalmic drugs.
About Medicilon
Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China. Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research. Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support. By the end of 2022, Medicilon has provided new drug R&D services to more than 1,840 clients around the world, and participated in the R&D of 330 new drug projects that have been approved for clinical trials. Medicilon is proud to contribute to human health in the globe.
marketing@medicilon.com
